Novartis AG is the second big pharma behind Pfizer Inc. to declare that it will hold off on raising the prices of any drugs in the US for the remainder of the year, as it awaits clarity on evolving drug policy.
CEO Vas Narasimhan announced the decision during the company's second quarter earnings call July 18 in which the company said it delivered strong sales of new drugs like Cosentyx (secukinumab)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?